These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 2145007

  • 1. Tamoxifen approved for node-negative breast cancer patients.
    Oncology (Williston Park); 1990 Aug; 4(8):15-6. PubMed ID: 2145007
    [No Abstract] [Full Text] [Related]

  • 2. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
    Voogd AC, Crommelin MA, Repelaer van Driel OJ, Tutein Nolthenius-Puylaert MC, Vreugdenhil G, Coebergh JW.
    Ned Tijdschr Geneeskd; 1998 Aug 01; 142(31):1772-8. PubMed ID: 9856143
    [Abstract] [Full Text] [Related]

  • 3. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA, Diamandis EP, Yu H, Look MP, Meijer-van Gelder ME, van Putten WL, Klijn JG.
    Br J Cancer; 1999 Feb 01; 79(5-6):888-94. PubMed ID: 10070886
    [Abstract] [Full Text] [Related]

  • 4. [The estrogen receptor in breast carcinoma in male patients and the tamoxifen response].
    Gómez Cruz P, Rivadeneyra Hinojosa J, García-Alonso H, Rábago Velasco M.
    Ginecol Obstet Mex; 1988 Nov 01; 56():310-4. PubMed ID: 2856451
    [No Abstract] [Full Text] [Related]

  • 5. Adjuvant therapy for node-negative breast cancer: a proactive view.
    Glick JH.
    Important Adv Oncol; 1990 Nov 01; ():183-97. PubMed ID: 2182518
    [No Abstract] [Full Text] [Related]

  • 6. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK, Ellard S, Norris B, Hayes M, Barnett J, Gelmon KA.
    Cancer; 2008 Apr 01; 112(7):1437-44. PubMed ID: 18286526
    [Abstract] [Full Text] [Related]

  • 7. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H, Skaland I, Varhaug JE, Kørner H, Janssen EA, Gudlaugsson E, Baak JP, Søreide JA.
    Acta Oncol; 2009 Apr 01; 48(4):514-21. PubMed ID: 19107621
    [Abstract] [Full Text] [Related]

  • 8. The role of adjuvant therapy in the management of node negative breast cancer.
    Young V, O'Connell PR, Keane FB.
    Ir Med J; 1990 Mar 01; 83(1):34-5. PubMed ID: 2361839
    [No Abstract] [Full Text] [Related]

  • 9. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M, MacGrogan G, Brouste V, Mathoulin-Pelissier S, Durand M, Mauriac L.
    Cancer; 2007 Jun 01; 109(11):2197-204. PubMed ID: 17450590
    [Abstract] [Full Text] [Related]

  • 10. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
    Jansson A, Delander L, Gunnarsson C, Fornander T, Skoog L, Nordenskjöld B, Stål O.
    Clin Cancer Res; 2009 May 15; 15(10):3610-6. PubMed ID: 19401349
    [Abstract] [Full Text] [Related]

  • 11. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 12. Adjuvant chemotherapy of early breast cancer.
    Med Lett Drugs Ther; 1990 May 18; 32(818):49-50. PubMed ID: 2333039
    [No Abstract] [Full Text] [Related]

  • 13. The management of locally advanced carcinoma of the breast by Nolvadex (tamoxifen): a pilot study.
    Campbell FC, Morgan DA, Bishop HM, Benton FM, Blamey RW, Elston CW, Nicholson RI, Griffiths K.
    Clin Oncol; 1984 Jun 18; 10(2):111-5. PubMed ID: 6734002
    [Abstract] [Full Text] [Related]

  • 14. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
    Kaufmann M, Graf E, Jonat W, Eiermann W, Geberth M, Albert US, Gademann G, Conrad B, Stahl K, von Minckwitz G, Schumacher M, German Adjuvant Breast Cancer Group.
    J Clin Oncol; 2005 Nov 01; 23(31):7842-8. PubMed ID: 16258087
    [Abstract] [Full Text] [Related]

  • 15. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
    Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S, Osborne CK.
    Clin Cancer Res; 1998 Jan 01; 4(1):7-12. PubMed ID: 9516946
    [Abstract] [Full Text] [Related]

  • 16. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.
    J Clin Oncol; 2008 Mar 20; 26(9):1404-10. PubMed ID: 18349391
    [Abstract] [Full Text] [Related]

  • 17. [Adjuvant tamoxifen in breast cancers with negative estrogen receptors. Complete review of the literature].
    Namer M, Poterre M.
    Bull Cancer; 1992 Mar 20; 79(3):297-9. PubMed ID: 1392169
    [No Abstract] [Full Text] [Related]

  • 18. Tamoxifen for patients with estrogen receptor-negative breast cancer.
    Swain SM.
    J Clin Oncol; 2001 Sep 15; 19(18 Suppl):93S-97S. PubMed ID: 11560981
    [No Abstract] [Full Text] [Related]

  • 19. Management of breast cancer with hormones and drugs.
    Lippman ME.
    Hosp Pract (Off Ed); 1986 May 15; 21(5):119-27, 131. PubMed ID: 3009506
    [No Abstract] [Full Text] [Related]

  • 20. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society.
    Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, Han W, Korean Breast Cancer Society.
    J Clin Oncol; 2007 Jun 10; 25(17):2360-8. PubMed ID: 17515570
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.